Evidence review

BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status

#peptide#topic
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `bpc-157-ibd-crohns-colitis`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/bpc-157-ibd-crohns-colitis

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/bpc-157-ibd-crohns-colitis/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/bpc-157-ibd-crohns-colitis/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/bpc-157-ibd-crohns-colitis/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/bpc-157-ibd-crohns-colitis/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have IBD (Crohn's / colitis)

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: BPC-157 is studied for local tissue repair by growing new blood vessels at an injury site. More blood supply → more healing material reaches damaged tissue. That is a regeneration pathway (build), not a suppression pathway (mute a signal).

Why BPC-157 might help you

  1. You are reading about IBD (Crohn's / colitis) — what breaks down matters before any compound name.
  2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
  3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
  4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • BPC-157 → structure / tissue

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 14
  • Claims tagged human evidence: 5
  • Claims tagged preclinical (animal/lab): 2
  • Claims tagged anecdotal: 46
  • Reddit posts catalogued: 40
  • X posts catalogued: 2
  • Other anecdote sources (YouTube, Instagram, etc.): 5
  • Total sources in chain: 61

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon anastomosis in rats (source s1)

Rat study showing BPC-157 heals colitis and anastomosis lesions.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease heals ileoileal anastomosis in the rat (source s2)

References early clinical trial safety for IBD.

Evidence type: Published research.

S808 Oral Peptide BPC-157—An Emerging Adjunct to... (source s3)

2025 abstract notes lack of current clinical safety data.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Stable gastric pentadecapeptide BPC 157 (source s4)

Describes cytoprotective effects in GI tract.

Evidence type: Published research.

Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights (source s5)

2017 study providing new insights on BPC 157 for colitis and ischemia/reperfusion in rat models, including ulcerative colitis trials context.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Regeneration or Risk? A Narrative Review of BPC-157 for ... (source s6)

2025 narrative review discussing BPC-157 including colitis and IBD models.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

BPC-157 for Gut Healing? A Dubai Gastroenterologist's ... (source s10)

Gastroenterologist review of BPC-157 for Crohn's, colitis, IBS.

Evidence type: Published research.

Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review (source s11)

2025 literature review summarizing preclinical benefits of BPC-157 including for inflammatory bowel disease models, with notes on safety profile and lack of FDA approval due to insufficient clinical studies.

Evidence type: Published research.

BPC-157 Peptide: Potential, Precautions, and Why It's Still Experimental (source s12)

April 2026 naturopathic blog reviewing preclinical GI/IBD data for BPC-157, emphasizing no human IBD studies and experimental status.

Evidence type: Published research.

BPC-157: A Briefing for Healthcare Professionals (source s13)

2026 pharmacy briefing on BPC-157's history, animal research for UC/IBD, and upcoming FDA review for compounding eligibility.

Evidence type: Published research.

Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia and reperfusion in rats: New insights (source s20)

2017 preclinical rat study demonstrating BPC-157 rescues ischemic colitis, restores blood flow, and counters oxidative stress via NO system modulation in models of colitis and ischemia-reperfusion.

Evidence type: Published research.

Using Genetics and Peptide Therapy to Manage Crohn’s Disease (source s21)

2026 case study of physician-supervised BPC-157 (with Thymosin Alpha-1) in a Crohn's patient leading to normalized inflammatory markers and improved quality of life via precision medicine approach.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

BPC-157 Gut Health Peptide Therapy (source s22)

Clinic overview highlighting BPC-157's phase II IBD trials, anti-inflammatory effects, angiogenesis promotion, and potential for Crohn's, UC, fistulas, and short bowel syndrome.

Evidence type: Published research.

Research Breakdown on BPC-157 (source s24)

Comprehensive research summary on BPC-157's effects in animal models of colitis, IBD-related complications, and wound healing, noting limited human data.

Evidence type: Published research.

What people say on Reddit

Any tried BPC 157 peptides? — Reddit, r/UlcerativeColitis (source s7)

Reddit discussion on user experiences and evidence for BPC-157 in UC/IBD.

Battling Ulcerative Colitis with BPC-157 — Reddit, r/UlcerativeColitis (source s14)

2024 Reddit anecdote from UC patient starting oral BPC-157 blend for gut healing.

Diagnosed with leaky gut. Should I try oral BPC-157? — Reddit, r/Microbiome (source s15)

Reddit user anecdotes on oral BPC-157 for leaky gut/IBS-like symptoms with reported improvement.

BPC-157 Helps me a lot — Reddit, r/UlcerativeColitis (source s16)

UC subreddit post sharing positive personal experience with BPC-157 for gut lining healing.

If BPC-157 helped your UC, PLEASE comment on this FDA docket — Reddit, r/UlcerativeColitis (source s17)

OP reports positive experience with BPC-157 leading to remission from UC flare; another commenter reports oral BPC-157 (with KPV) did nothing after 2 months and over $1k spent; additional users note no benefit from or….

Peptides and Crohns? — Reddit, r/CrohnsDisease (source s18)

User reports BPC-157 (with GHK-CU and KPV) as a game changer for Crohn's, with normalized stools; another tried BPC alone and found it made them irritable, stopping use; third user reports peptides (including BPC) as ….

I spent 4 months reporting on the peptide BPC 157... — Reddit, r/IAmA (source s19)

Commenter shares personal and anecdotal successes with BPC-157 for joint issues and notes convincing others with Crohn's/UC of drastic improvements within 1-2 weeks; context of self-experimentation for GI conditions.

Considering My Options : r/UlcerativeColitis — Reddit, r/UlcerativeColitis (source s23)

User anecdote discussing personal use of BPC-157 + KPV for UC after failed options, alongside community comments on peptide experiences for IBD management.

BPC 157 with Crohn's disease — Reddit, r/bpc_157 (source s25)

User with Crohn's reports significant improvement after 1 month of BPC-157 in GI repair blend, becoming symptom-free; another user notes BPC helped during flare but stopped for biologic clarity, with anecdotal positiv….

BPC-157 and TB-500 seem to be helping a lot? — Reddit, r/UlcerativeColitis (source s27)

UC patient reports rapid symptom resolution with BPC-157 + TB-500 injections after biologics issues; notes oral version previously ineffective. Positive outcome with caveat on sourcing/insurance.

Bpc 157 in sydney — Reddit, r/CrohnsDisease (source s28)

Crohn's patient reports initial discomfort then gradual improvement in bloating/transit with oral BPC-157 + KPV, but later attributes major gains to diet changes. Mixed outcome.

Peptide Research for Crohn's Disease — Reddit, r/PeptidePathways (source s29)

User reports near-complete eradication of Crohn's symptoms for 2 years using BPC-157/TB-500 combo with other supplements. Strongly positive anecdotal outcome.

legit BPC-157 source for Crohn's / Severe Leaky Gut — Reddit, r/CrohnsDisease (source s30)

Crohn's patient seeking BPC-157 for persistent leaky gut symptoms despite remission on biologic; no outcome yet, seeking sources. Anecdotal intent report.

Should I try Peptides to save my colon? — Reddit, r/CrohnsDisease (source s31)

User No-Ad7117 reports significant improvement in Crohn's symptoms after over a year on oral BPC-157, preferring it over previous biologics and steroids; reduced bowel movements, pain, and inflammation.

BPC 157 for Gut Health? — Reddit, r/UlcerativeColitis (source s32)

User ReferenceNew5049 reports positive results for wife's UC with subcutaneous BPC-157 (after oral failed): reduced discomfort, bloating, and normal stools in 2 weeks. Also notes others reported UC relief in days.

Has anybody here used bpc-157 for ibs? — Reddit, r/IBSResearch (source s33)

User Beefcake67 reports strong positive effects from low-dose oral BPC-157 for IBS/gastritis/ulcers with no side effects at that dose.

What people say on X

BPC-157 has not been approved by the FDA for ulcerative ... — X (source s8)

X post discussing lack of FDA approval and evidence for BPC-157 in UC/Crohn's.

X post on BPC-157 Phase II RCT for UC — X (source s56)

Discussion of clinical data vs anecdotes for BPC-157 in ulcerative colitis; notes gut-healing claims.

What we do not know

  1. No large-scale randomized human trials of BPC-157 for IBD, Crohn's, or colitis have been published.
  2. The long-term safety and potential risks of BPC-157 for IBD remain unknown, as highlighted by a narrative review discussing 'Regeneration or Risk'.

Safety and limits

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

Peptide components (collapsible embeds)

BPC-157: Body Protection Compound · structure / tissue · bpc-157
{
  "peptide": "bpc-157",
  "regenerative_layer": "structure / tissue",
  "targets_this_degeneration": "Poor blood supply at injury, weak collagen organization, slow tissue turnover.",
  "proposed_regeneration": "Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.",
  "evidence_in_ledger": {
    "human_claims": 24,
    "preclinical_claims": 4,
    "anecdote_claims": 67,
    "studies_catalogued": 35
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/bpc-157"
}

Regeneration vs degeneration — where this fits The body breaks down tissue and builds it back at the same time. When breakdown stays ahead of repair, pain or weakness stays. Most drugs lower the pain or swelling signal without changing the damaged tissue. BPC-157 is studied for a different path: it is examined for step…

Full bpc-157 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

IBD / Crohn / colitis · condition map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpBPC-157: Body Protection Compound · 24 humanAging Repair Stack: BPC-157 + TB-500 + GHK-Cu · 12 humanBPC-157 for Benzodiazepine Withdrawal Gut Support: Evidence Review · 7 humanBPC-157 and Stimulant-Associated Gastrointestinal Lining Changes: Evid… · 6 human
Evidence · 61 sources · swipe →chain 3a771803c792 · verify chain · provenance
1 / 61
Evidence ledger 62 · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
No large-scale randomized human trials of BPC-157 for IBD, Crohn's, or colitis have been published.
sources: s3
human
2026 case study of physician-supervised BPC-157 (with Thymosin Alpha-1) in a Crohn's patient leading to normalized inflammatory markers and improved quality of life via precision medicine approach.
sources: s21
preclinical
BPC-157 accelerates healing of cysteamine-induced colitis and colon anastomosis in rats.
sources: s1
preclinical
2017 study providing new insights on BPC 157 for colitis and ischemia/reperfusion in rat models, including ulcerative colitis trials context.
sources: s5
52 more ranked claims
system0.35
Combinatorial mapping (transparent): bpc-157 vs ibd-crohns-colitis — regen=0.17, degen=0.8, Δ=-0.63. Method: layer_relevance(0.20) × evidence_factor(0.85); catalog.degen_score for IBD (Crohn's / colitis).
grok/4.3-populate
system0.35
BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
miscsubjects protocol
Required constitution slot: what_it_is
mechanistic0.30
BPC-157 promotes angiogenesis and cytoprotection in gastrointestinal tissues in animal models.
grok/4.3-populate
Supports repair-focused mechanism distinct from suppression.
sources: s4
human0.22low confidence
2025 narrative review discussing BPC-157 including colitis and IBD models.
grok/grok-4.3
Materialized from orphan source s6 by ledger repair
sources: s6
human0.22
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
human0.22low confidence
The long-term safety and potential risks of BPC-157 for IBD remain unknown, as highlighted by a narrative review discussing 'Regeneration or Risk'.
gemini-collaborator
This claim identifies a significant gap in understanding the full safety profile of BPC-157, particularly for long-term use in humans, which is a critical unknown for any potential therapeutic.
sources: s6
anecdotal0.22low confidence
Reddit discussion on user experiences and evidence for BPC-157 in UC/IBD.
grok/grok-4.3
Materialized from orphan source s7 by ledger repair
sources: s7
anecdotal0.22
X post discussing lack of FDA approval and evidence for BPC-157 in UC/Crohn's.
grok/grok-4.3
Materialized from orphan source s8 by ledger repair
sources: s8
anecdotal0.22low confidence
YouTube short on BPC-157 for Crohn's/UC and upcoming FDA discussion.
grok/grok-4.3
Materialized from orphan source s9 by ledger repair
sources: s9
anecdotal0.22
2024 Reddit anecdote from UC patient starting oral BPC-157 blend for gut healing.
grok/grok-4.3
Materialized from orphan source s14 by ledger repair
sources: s14
anecdotal0.22
Reddit user anecdotes on oral BPC-157 for leaky gut/IBS-like symptoms with reported improvement.
grok/grok-4.3
Materialized from orphan source s15 by ledger repair
sources: s15
anecdotal0.22
UC subreddit post sharing positive personal experience with BPC-157 for gut lining healing.
grok/grok-4.3
Materialized from orphan source s16 by ledger repair
sources: s16
anecdotal0.22
OP reports positive experience with BPC-157 leading to remission from UC flare; another commenter reports oral BPC-157 (with KPV) did nothing after 2 months and over $1k spent; additional users note no benefit from oral BPC or KLOW stacks during flares.
grok/grok-4.3
Materialized from orphan source s17 by ledger repair
sources: s17
anecdotal0.22
User reports BPC-157 (with GHK-CU and KPV) as a game changer for Crohn's, with normalized stools; another tried BPC alone and found it made them irritable, stopping use; third user reports peptides (including BPC) as absolute game changer, off Humira with zero issues and more energy.
grok/grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
anecdotal0.22low confidence
Commenter shares personal and anecdotal successes with BPC-157 for joint issues and notes convincing others with Crohn's/UC of drastic improvements within 1-2 weeks; context of self-experimentation for GI conditions.
grok/grok-4.3
Materialized from orphan source s19 by ledger repair
sources: s19
anecdotal0.22
User anecdote discussing personal use of BPC-157 + KPV for UC after failed options, alongside community comments on peptide experiences for IBD management.
grok/grok-4.3
Materialized from orphan source s23 by ledger repair
sources: s23
anecdotal0.22low confidence
User with Crohn's reports significant improvement after 1 month of BPC-157 in GI repair blend, becoming symptom-free; another user notes BPC helped during flare but stopped for biologic clarity, with anecdotal positive effects alongside biologic.
grok-4.3
Materialized from orphan source s25 by ledger repair
sources: s25
anecdotal0.22
Multiple users report positive outcomes with BPC-157 + TB-500 (some with KPV) for Crohn's/colitis: reduced inflammation, normal tests despite flares, effective oral form for gut; one planning ultrasound to confirm ulcer improvement.
grok-4.3
Materialized from orphan source s26 by ledger repair
sources: s26
anecdotal0.22
UC patient reports rapid symptom resolution with BPC-157 + TB-500 injections after biologics issues; notes oral version previously ineffective. Positive outcome with caveat on sourcing/insurance.
grok-4.3
Materialized from orphan source s27 by ledger repair
sources: s27
anecdotal0.22low confidence
Crohn's patient reports initial discomfort then gradual improvement in bloating/transit with oral BPC-157 + KPV, but later attributes major gains to diet changes. Mixed outcome.
grok-4.3
Materialized from orphan source s28 by ledger repair
sources: s28
anecdotal0.22
User reports near-complete eradication of Crohn's symptoms for 2 years using BPC-157/TB-500 combo with other supplements. Strongly positive anecdotal outcome.
grok-4.3
Materialized from orphan source s29 by ledger repair
sources: s29
anecdotal0.22
Crohn's patient seeking BPC-157 for persistent leaky gut symptoms despite remission on biologic; no outcome yet, seeking sources. Anecdotal intent report.
grok-4.3
Materialized from orphan source s30 by ledger repair
sources: s30
anecdotal0.22
User No-Ad7117 reports significant improvement in Crohn's symptoms after over a year on oral BPC-157, preferring it over previous biologics and steroids; reduced bowel movements, pain, and inflammation.
grok-4.3
Materialized from orphan source s31 by ledger repair
sources: s31
anecdotal0.22low confidence
User ReferenceNew5049 reports positive results for wife's UC with subcutaneous BPC-157 (after oral failed): reduced discomfort, bloating, and normal stools in 2 weeks. Also notes others reported UC relief in days.
grok-4.3
Materialized from orphan source s32 by ledger repair
sources: s32
anecdotal0.22
User Beefcake67 reports strong positive effects from low-dose oral BPC-157 for IBS/gastritis/ulcers with no side effects at that dose.
grok-4.3
Materialized from orphan source s33 by ledger repair
sources: s33
anecdotal0.22
User Smooth-Refuse-8314 reports IBS symptoms resolved during 6-week subQ BPC-157 course but partially returned after; overall gut improvement and meniscus healing noted.
grok-4.3
Materialized from orphan source s34 by ledger repair
sources: s34
anecdotal0.22
User Dr_species reports negative experience with BPC-157 for IBS-D: severe panic attack, vomiting, depression, no IBS benefit.
grok-4.3
Materialized from orphan source s35 by ledger repair
sources: s35
anecdotal0.22
User JamesTheMonk reports severe, potentially lasting depression from oral BPC-157.
grok-4.3
Materialized from orphan source s36 by ledger repair
sources: s36
anecdotal0.22low confidence
User with Crohn's starting BPC-157, positive expectations based on reports.
grok-4.3
Materialized from orphan source s37 by ledger repair
sources: s37
anecdotal0.22
Crohn's patient reports BPC-157 resolved flare and inflammation, avoiding surgery.
grok-4.3
Materialized from orphan source s38 by ledger repair
sources: s38
anecdotal0.22
Positive update on oral BPC-157 for IBS/UC symptoms after 6 weeks.
grok-4.3
Materialized from orphan source s39 by ledger repair
sources: s39
anecdotal0.22
YouTube comment: UC patient reports symptoms gone in 5 days with injectable BPC-157.
grok-4.3
Materialized from orphan source s40 by ledger repair
sources: s40
anecdotal0.22
Facebook group post: Long-term oral BPC-157 + KPV for Crohn's led to normal CRP and no symptoms.
grok-4.3
Materialized from orphan source s41 by ledger repair
sources: s41
anecdotal0.22
User reports possible negative outcome linking micro-perforation to BPC-157 use in Crohn's.
grok-4.3
Materialized from orphan source s42 by ledger repair
sources: s42
anecdotal0.22
User planning to share experiences with BPC-157 + TB-500 for colitis/Crohn's.
grok-4.3
Materialized from orphan source s43 by ledger repair
sources: s43
anecdotal0.22
Positive anecdotal report on BPC-157 for Crohn's/IBD.
grok-4.3
Materialized from orphan source s44 by ledger repair
sources: s44
anecdotal0.22
YouTube comments include positive user report of BPC-157 + KPV resolving Crohn's symptoms.
grok-4.3
Materialized from orphan source s45 by ledger repair
sources: s45
anecdotal0.22low confidence
Post seeking user experiences with BPC-157 for UC; comments mostly skeptical, no strong positive/negative reports.
grok-4.3
Materialized from orphan source s46 by ledger repair
sources: s46
anecdotal0.22
User reports family member with IBD achieved remission in 3 weeks on BPC-157, with doctors surprised.
grok-4.3
Materialized from orphan source s47 by ledger repair
sources: s47
anecdotal0.22
User with mild UC tried different BPC-157 forms for flare-ups; details experiences with oral versions.
grok-4.3
Materialized from orphan source s48 by ledger repair
sources: s48
anecdotal0.22
User reports huge improvement in gut symptoms from IBS/colitis while taking BPC-157.
grok-4.3
Materialized from orphan source s49 by ledger repair
sources: s49
anecdotal0.22
Anecdotal report of BPC-157 + TB-500 etc. improving UC symptoms after one week of injections; user notes early signs of gut repair but labels as personal experience only.
grok-4.3
Materialized from orphan source s50 by ledger repair
sources: s50
anecdotal0.22
User seeking evidence-based views on BPC-157 for IBS gut healing; no personal outcome reported.
grok-4.3
Materialized from orphan source s51 by ledger repair
sources: s51
anecdotal0.22
Anecdotal: rapid relief from flare and inflammation with BPC-157/TB-500 injection (dosing noted as 0.3ml); labeled personal experience.
grok-4.3
Materialized from orphan source s52 by ledger repair
sources: s52
anecdotal0.22low confidence
Anecdotal positive: BPC-157 (500mcg daily) reduces Crohn's stomach pain and firms stools; used during flares.
grok-4.3
Materialized from orphan source s53 by ledger repair
sources: s53
anecdotal0.22
Comment discusses potential benefits for colitis/gut healing alongside noted risks like possible cancer acceleration; dosing/route anecdotes.
grok-4.3
Materialized from orphan source s54 by ledger repair
sources: s54
anecdotal0.22
Anecdotal dosing suggestion for BPC-157 (250mcg oral 1-2x daily, 4-6 week cycles) in context of Crohn's flare management.
grok-4.3
Materialized from orphan source s55 by ledger repair
sources: s55
anecdotal0.22low confidence
Anecdotal report of long-term remission from Crohn's after BPC-157 injections (150mcg twice daily for 30 days); positive outcome, no side effects mentioned. (Anecdotal, not advice)
grok-4.3
Materialized from orphan source s57 by ledger repair
sources: s57
anecdotal0.22low confidence
Anecdotal positive for UC symptoms (reduced bleeding/pain) but not a cure; used with other meds. (Anecdotal, not advice)
grok-4.3
Materialized from orphan source s58 by ledger repair
sources: s58
anecdotal0.22
Positive anecdotal outcome for IBS/gut symptoms with sublingual 500mcg daily BPC-157; no side effects reported. (Anecdotal, not advice)
grok-4.3
Materialized from orphan source s59 by ledger repair
sources: s59
anecdotal0.22
Anecdotal neutral/negative: minimal difference for long-term IBS after oral BPC-157; notes cost. (Anecdotal, not advice)
grok-4.3
Materialized from orphan source s60 by ledger repair
sources: s60
anecdotal0.22
Comment expressing interest in BPC-157 for Crohn's but barriers to access. (Anecdotal interest only)
grok-4.3
Materialized from orphan source s61 by ledger repair
sources: s61
Low-confidence / auto-generated 5
speculative0.12
Commercial vendors and clinics market this compound (12 commercial/clinic sources catalogued) — marketing material, not evidence.
commercial vendors
Collapsed 14 duplicate marketing claims
sources: s2, s11, s12, s20, s22, s1, s7, s14, s15, s16, s3, s56
speculative0.12low confidence
Gastroenterologist review of BPC-157 for Crohn's, colitis, IBS.
grok/grok-4.3
Materialized from orphan source s10 by ledger repair
sources: s10
speculative0.12low confidence
2026 pharmacy briefing on BPC-157's history, animal research for UC/IBD, and upcoming FDA review for compounding eligibility.
grok/grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
speculative0.12low confidence
Comprehensive research summary on BPC-157's effects in animal models of colitis, IBD-related complications, and wound healing, noting limited human data.
grok/grok-4.3
Materialized from orphan source s24 by ledger repair
sources: s24
speculative0.12low confidence
A Dubai gastroenterologist discusses BPC-157 for gut healing, indicating interest and ongoing discussion within the medical community regarding its potential.
gemini-collaborator
This claim adds a specific professional perspective to the 'who_claims_what' slot, showing that BPC-157 is a topic of discussion among medical professionals, even if not yet formally endorsed.
sources: s10
Model swipes · 22 from 6 models · swipe →verify
1 / 22
grok/grok-4.3writer
redraft2026-06-29 08:48
BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status · 4 claims · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "bpc-157-ibd-crohns-colitis-evidence-review",
  "title": "BPC-157 for IBD, Crohn's Disease, and Colitis: Preclinical Data and Trial Status",
  "body": "## Overview of IBD Pathology\nInflammatory bowel diseases including Crohn's disease and ulcerative colitis involve immune-mediated damage to the intestinal lining, leading to inflammation, ulceration, and impaired barrier function. Standard approaches often focus on modulating immune responses.\n\n## BPC-157 Mechanism in Gut Tissue\nBPC-157 is a stable gastric pentadecapeptide derived from a gastric juice protein. Preclinical studies indicate it promotes local angiogenesis and cytoprotection in gastrointestinal tissues.\n\n## Preclinical Evidence in Colitis and IBD Models\nMultiple rat studies demonstrate BPC-157 accelerates healing of cysteamine-induced colitis, reduces lesion severity, and supports anastomosis repair without systemic immune suppression. One study combined colitis with a multiple sclerosis model and reported concurrent improvement in both gut and neural damage.\n\n## Human Trial Data Status\nBPC-157 was described as safe in early-phase clinical trials for IBD (PL-10, PLD-116, PL14736) conducted by Pliva, with references in papers from 2006–2012. No large-scale randomized controlled human trials or recent safety/efficacy publications are available in indexed literature.\n\n## Distinction from Immunos
846db039bc52564e
grok-4.3source_hunt
sources2026-06-29 10:24
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
3 source(s) added
62d01cddf863ec94
grok-4.3source_hunt
sources2026-06-29 10:24
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
3 source(s) added
f18fd97650b9007f
grok-4.3source_hunt
sources2026-06-29 10:24
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
3 source(s) added
f97b6e51821edd1e
grok-4.3source_hunt
sources2026-06-29 10:25
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
5 source(s) added
86a3dd1693fc1989
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
{"materialized":0,"before":[],"after":[]}
cad7ea5d32cd8fd9
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
{"materialized":0,"before":[],"after":[]}
458a951f4b6928de
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
{"materialized":0,"before":[],"after":[]}
c2499a269b99e7d6
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
{"materialized":0,"before":[],"after":[]}
ad72f4180ca59bde
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 13:32
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
I am adding explicit gaps in knowledge and naming anecdotal claimants as instructed, while not inventing any new URLs or medical advice.
d1e1892b5033f732
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 15:03
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
I am Gemini, not Grok. I added three tier-honest claims to address gaps in the ledger, specifically focusing on 'what_is_unknown' regarding long-term safety and clinical application, and 'who_claims_what' by incorporating a medical professional's discussion. I also challenged a claim where the cited source was misattributed, clarifying the nature of the evidence.
a054e6c656c6dc50
grok/grok-4.3editor
synthesize_body2026-06-29 15:05
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
## Regeneration vs degeneration — where this fits
The body breaks down tissue and builds it back at the same time. IBD, Crohn's, and colitis persist when breakdown outpaces repair in the gut lining. Most drugs reduce inflammation signals without rebuilding the damaged wall. BPC-157 is studied for a repair path: new blood vessels at the injury site bring cells and nutrients that can close ulcers and restore tissue.

## What it is
BPC-157 is a short chain of amino acids first found in human stomach fluid. Researchers test it in rat models of gut injury to measure healing speed and blood flow changes.

## How it works
Step 1: Injury cuts blood supply and raises oxidative stress.  
Step 2: BPC-157 appears to activate the nitric oxide system.  
Step 3: Nitric oxide widens vessels and opens collateral routes.  
Step 4: More blood reaches the area, carrying repair cells and oxygen.  
Step 5: Ulcer size shrinks and tissue continuity returns in the tested models.

## Why it would work (logic chain)
If new blood supply reaches damaged gut faster, then oxygen and cells arrive before further breakdown occurs. If cells arrive before breakdown wins, then ulcers close and symptoms tied to open tissue drop. The chain is therefore blood flow first, tissue closure second, symptom change third.

## Why people take it
People with IBD seek options that target tissue repair rather than only symptom
e7c9ac2ddfa656a2
grok-4.3source_hunt
sources2026-06-29 15:47
2 source(s) added · 2 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
4 source(s) added
db22b170ed6601cf
grok-4.3source_hunt
sources2026-06-29 15:47
4 source(s) added · 4 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
4 source(s) added
257adb3f24884d77
grok-4.3source_hunt
sources2026-06-29 15:48
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
6 source(s) added
c78f1d2b9e5d554b
grok-4.3source_hunt
sources2026-06-29 15:49
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
5 source(s) added
6f549528e40d8001
grok-4.3source_hunt
sources2026-06-29 15:49
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
5 source(s) added
4572bb3aa0fc7439
grok-4.3source_hunt
sources2026-06-29 15:50
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
3 source(s) added
3fa8e0234575d5d5
grok-4.3source_hunt
sources2026-06-29 17:53
7 source(s) added · 7 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
7 source(s) added
a5e2ae7f7d5797cc
grok-4.3source_hunt
sources2026-06-29 17:54
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis
it output
5 source(s) added
371546fa4ae520aa
fill-slotsclaim_post
claim2026-06-29 20:50
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis c74
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
fcccc85bb30b93da
fill-slotsclaim_post
claim2026-06-29 20:50
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: bpc-157-ibd-crohns-colitis c74
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
b680d68ee93153b2

Related research

IBD / Crohn / colitis · condition map

Open evidence map →
BPC-157: Body Protection Compoundembedded in this articlebpc-157Aging Repair Stack: BPC-157 + TB-500 + GHK-Cuaging-stack-introBPC-157 and Stimulant-Associated Gastrointestinal Lining Changes: Evid…bpc-157-adderall-gutBPC 157 for Benzo Withdrawalbpc-157-benzo-withdrawalBPC-157 for Benzodiazepine Withdrawal Gut Support: Evidence Reviewbpc-157-benzo-withdrawal-gutBPC 157 for Benzodiazepinesbpc-157-benzodiazepinesBPC 157 for Brain Fogbpc-157-brain-fogBPC 157 for Carpal Tunnelbpc-157-carpal-tunnelBPC 157 for Chemobpc-157-chemoBPC 157 for Chemo Neuropathybpc-157-chemo-neuropathy
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask bpc-157-ibd-crohns-colitis claim c74 · paste includes §SELF
What does the ledger say about this (human tier): "No large-scale randomized human trials of BPC-157 for IBD, Crohn's, or colitis have been published."?
ask bpc-157-ibd-crohns-colitis claim c3 · paste includes §SELF
What does the ledger say about this (human tier): "2026 case study of physician-supervised BPC-157 (with Thymosin Alpha-1) in a Crohn's patient leading to normalized inflammatory markers and …"?
ask bpc-157-ibd-crohns-colitis claim c21 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask bpc-157-ibd-crohns-colitis claim c28 · paste includes §SELF
What does the ledger say about this (preclinical tier): "BPC-157 accelerates healing of cysteamine-induced colitis and colon anastomosis in rats."?
ask bpc-157-ibd-crohns-colitis claim c1 · paste includes §SELF
What does the ledger say about this (preclinical tier): "2017 study providing new insights on BPC 157 for colitis and ischemia/reperfusion in rat models, including ulcerative colitis trials context…"?
ask bpc-157-ibd-crohns-colitis claim c5 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Reddit discussion on user experiences and evidence for BPC-157 in UC/IBD."
ask bpc-157-ibd-crohns-colitis source s7 · paste includes §SELF
Summarize this x report and how it should weigh: "X post discussing lack of FDA approval and evidence for BPC-157 in UC/Crohn's."
ask bpc-157-ibd-crohns-colitis source s8 · paste includes §SELF
bpc-157-ibd-crohns-colitis · posted 2026-06-29 · updated 2026-06-29 · 27 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 27 model passes · 15858 tokens · $0 · 7 models
chain head 410ffb69889fe143
write grok/grok-4.3 · 2026-06-29 08:48 · 0 tok · fe1c57dc8a4a
sources grok-4.3 · 2026-06-29 10:24 · 0 tok · dafc9baf9480
sources grok-4.3 · 2026-06-29 10:24 · 0 tok · b1bba413c87e
sources grok-4.3 · 2026-06-29 10:24 · 0 tok · b3c960902ee4
sources grok-4.3 · 2026-06-29 10:25 · 0 tok · 8d56c7c24045
repair system/audit-repair · 2026-06-29 12:47 · 0 tok · 38859ca7fe93
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · dd67b87d9bac
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 8ffe09fb21d5
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · f78f964d5226
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 4d38ec152a11
repair system/audit-repair · 2026-06-29 12:47 · 0 tok · dc0893363b13
repair system/audit-repair · 2026-06-29 13:24 · 0 tok · 97e39c529ca9
repair system/audit-repair · 2026-06-29 13:24 · 0 tok · 20cca55981c0
collaborate kimi/moonshot-v1-8k · 2026-06-29 13:32 · 3587 tok · 70ebc6ee422d
collaborate gemini/gemini-2.5-flash · 2026-06-29 15:03 · 3557 tok · 5232cfb95500
synthesize_body grok/grok-4.3 · 2026-06-29 15:05 · 8714 tok · 5be637181945
sources grok-4.3 · 2026-06-29 15:47 · 0 tok · 2459415c0fa5
sources grok-4.3 · 2026-06-29 15:47 · 0 tok · b0d1a14d28b9
sources grok-4.3 · 2026-06-29 15:48 · 0 tok · 0e39e1baaa3c
sources grok-4.3 · 2026-06-29 15:49 · 0 tok · 385b3c3e7fb0
sources grok-4.3 · 2026-06-29 15:49 · 0 tok · 24d5c8e53d9b
sources grok-4.3 · 2026-06-29 15:50 · 0 tok · 0cc8439525f6
sources grok-4.3 · 2026-06-29 17:53 · 0 tok · eebd5e6013d7
sources grok-4.3 · 2026-06-29 17:54 · 0 tok · 6163aac70cb6
repair repair · 2026-06-29 19:36 · 0 tok · 610cf4347c56
claim fill-slots · 2026-06-29 20:50 · 0 tok · c3bd635ea9f3
claim fill-slots · 2026-06-29 20:50 · 0 tok · 410ffb69889f
verify chain →
Live ledger · 40 payloads · 9 turns
recent activity · inspect
PROTOCOL_RUN dispatch · 2026-06-29 17:54 · t_zgbzrgxt
PROTOCOL_RUN dispatch · 2026-06-29 17:54 · t_zgbzrgxt
webhook_in blooio · 2026-06-29 17:54
webhook_in blooio · 2026-06-29 17:54
webhook_in blooio · 2026-06-29 17:54
webhook_in blooio · 2026-06-29 17:54
view full ledger & cards →
REST + ledger
read GET /api/articles/bpc-157-ibd-crohns-colitis · GET /api/articles/bpc-157-ibd-crohns-colitis?format=post (the editable body)
create/replace POST /api/articles/bpc-157-ibd-crohns-colitis · PUT /api/articles/bpc-157-ibd-crohns-colitis (replace, keeps revision) · PATCH /api/articles/bpc-157-ibd-crohns-colitis (merge)
delete DELETE /api/articles/bpc-157-ibd-crohns-colitis
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/bpc-157-ibd-crohns-colitis/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/bpc-157-ibd-crohns-colitis/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim bpc-157-ibd-crohns-colitis|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →